A single-blinded randomized, placebo-controlled, staggered-parallel, escalating-dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in subjects with type 2 diabetes mellitus.

Trial Profile

A single-blinded randomized, placebo-controlled, staggered-parallel, escalating-dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in subjects with type 2 diabetes mellitus.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2016

At a glance

  • Drugs Albiglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 31 Jul 2009 Actual end date Sep 2006 added as reported by ClinicalTrials.gov.
    • 07 Nov 2008 Basic check conducted, last updated 9-10-2008.
    • 12 Oct 2008 Trial phase changed from I to II as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top